| Autor: |
English, Emily P., Swingler, Rachel N., Patwa, Simran, Tosun, Mehmet, Howard Jr., James F., Miljković, Miloš D., Jewell, Christopher M. |
| Předmět: |
|
| Zdroj: |
Science Translational Medicine; 10/30/2024, Vol. 16 Issue 771, p1-16, 16p |
| Abstrakt: |
Chimeric antigen receptor-T cell (CAR-T) therapy has transformed the management of refractory hematological malignancies. Now that targeting pathogenic cells of interest with antigen-directed cytotoxic T lymphocytes is possible, the field is expanding the reach of CAR-T therapy beyond oncology. Recently, breakthrough progress has been made in the application of CAR-T technology to autoimmune diseases, exploiting the same validated targets that were used by pioneering CAR-T therapies in hematology. Here, we discuss recent advances and outcomes that are paving the way for extension to new therapeutic areas, including autoimmunity. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
